JOINN

JOINN Laboratories surged 5.05% to close at HKD 23.30 in the morning session, driven by a rally in experimental monkey prices and a sharp profit forecast for the interim period, alongside Q1 2026 net profit soaring 513.64% YoY to HKD 270 million, with EPS of HKD 0.3628 and revenue up 16.47% YoY to HKD 358 million. Despite operating income still negative at HKD -34.9 million, net profit margin improved to 75.40%. The stock is trading 22.28% below its 52-week high of HKD 29.98, yet above MA20 (HKD 22.78) and MA60 (HKD 19.87), with YTD gain of 16.73%, PE of 31.14x, PB of 1.80x, and market cap of HKD 17.5 billion. However, the company previously warned of overheated sentiment and irrational speculation risk.

Joinn Laboratories (6127.HK) experienced a volatile session, surging to an intraday high of 23.72 HKD in the morning before retreating to close at 22.00 HKD, down 6.78% from the previous close of 23.60 HKD. The decline was primarily driven by profit-taking after a recent sharp rally fueled by the company's interim profit alert, which forecasted net profit to surge up to 13.77 times year-on-year to 900 million HKD, supported by rising experimental monkey prices boosting biological asset valuations. The stock has now corrected 26.6% from its 52-week high of 29.98 HKD on July 15. Turnover reached approximately 163 million HKD with a turnover rate of 6.15%, indicating heightened divergence. Q1 2026 net profit jumped 513.6% YoY to 270 million HKD, though operating income remained negative. The stock trades at a PE of 29.4x and PB of 1.7x, and has fallen below its 20-day moving average of 22.58 HKD, while still above the 60-day MA of 19.82 HKD.

JOINN Lab (6127.HK) had a volatile morning session, opening at HK$25.06 and briefly touching an intraday high of HK$25.24 before retreating to HK$23.76, marking a 4.8% decline. The pullback follows a recent surge driven by a rally in experimental monkey prices and a positive profit alert, which guided interim net profit to soar up to 8.85x year-on-year to around RMB900 million. Q1 2026 net profit jumped 513.64% YoY to HK$270.2 million, with a net profit margin of 75.4%, though operating income remained negative. At HK$23.82, the stock sits 20.55% below its 52-week high of HK$29.98 but above both its 20-day MA (HK$22.17) and 60-day MA (HK$19.77), with a YTD gain of 19.34%. However, the company cautioned against overheated market sentiment and irrational speculation in a recent notice.

JOINN Laboratories surged 5.31% in the morning session to close at HKD 25.76, driven by a CRO sector rally and rising research monkey prices, with intraday low of HKD 24.78 and high of HKD 25.76, on volume of 1.25 million shares. The company's interim profit alert projected a net profit surge of up to 13.77x year-over-year to RMB 900 million, mainly from biological asset gains, while Q1 net profit already jumped 513.64% YoY to HKD 270 million. YTD return stands at 29.06%, still 14.08% below the 52-week high of HKD 29.98, but above both the MA20 (HKD 21.99) and MA60 (HKD 19.77). However, operating income remained negative for two consecutive quarters, with a Q1 loss of HKD 34.9 million, indicating underlying business pressure.

JOINN Laboratories surged in the morning session, opening higher and climbing steadily to close at HKD 26.32, up 4.95% from the previous close of HKD 25.06, driven by a Q1 net profit surge of 513.64% YoY to HKD 270 million, with net profit margin jumping from 32.28% in Q4 to 75.40%. The intraday low was HKD 25.40 and high HKD 26.32, with turnover of HKD 54 million. The stock has rebounded 73.83% from its 52-week low of HKD 15.13, but remains 12.27% below the 52-week high of HKD 29.98, with a YTD gain of 31.76%. It now trades above both the 20-day MA (HKD 21.34) and 60-day MA (HKD 19.71). However, operating income remained negative, with a loss of HKD 34.9 million in Q1, suggesting underlying operational profitability is still weak.